Amgen Inc. (AMG MU) stock market data APIs
€328.6832
0(0%)
as of September 18, 2026
Try our APIs with
free plan!
Amgen Inc. Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for AMG.MU.
Prev. Close
328.6832
Open
328.6832
High
328.6832
Low
328.6832
52 wk Range
227.3564-382.45
Market Cap
105 182 M
EPS
2.17
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amgen Inc. data using free add-ons & libraries
Get Amgen Inc. Fundamental Data
Amgen Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2018-06-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amgen Inc. News
New
Amgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh Pipeline Risks
Amgen's updated analyst model now points to a fair value price target of US$388.03, compared with the prior US$371.93. This provides a slightly higher anchor for how the stock is being valued today. T...
Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing
Amgen (AMGN) closed the most recent trading day at $385.65, moving +1.55% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.17%. Meanwhile, the Dow lost 0.18%, and th...
Top Research Reports for AMD, Linde & Amgen
Friday, September 18, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Advance...
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
Bristol Myers BMY recently announced positive two-year results from the late-stage POETYK PsA-2 study on Sotyktu (deucravacitinib), including its open-label extension (OLE). The two-year data provide...
Get Amgen Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
